Drug Research
Drug Discovery & Development

Dynavax Receives NIH Grant To Develop Papilloma Virus Vaccine

PBR Staff Writer Published 07 July 2010

Dynavax Technologies has received a grant of $600,000 from the National Institutes of Health (NIH) to study the probability of developing a vaccine against infection by human papilloma virus (HPV).

In contradiction to the two approved HPV vaccines that target approximately 70% of HPV strains, Dynavax Technologies is into developing a vaccine that provides immunity to nearly all cancer-causing strains of HPV.

Dynavax Technologies is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious diseases.

Dynavax Technologies' lead product candidate Heplisav is an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines.

Heplisav is known to combine hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist known as ISS to enhance the immune response.